← Russell 3000 cross-section

ASMB ASSEMBLY BIOSCIENCES, INC.

Trailing twelve months to 2026-06-30 · as filed 2026-08-13, not restated
Healthcare

Scale

Market cap
$728m
Revenue TTM
$75m
Net income TTM
$0m
Free cash flow
$-39m
Composite score
61.2
Sector rank
#2210

Valuation

P / E
EV / EBITDA
EV / sales
5.4
FCF yield
-5.30%
Earnings yield vs 10-yr
-4.73pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-0.1%
EBITDA margin
-11.6%
ROE
-0.0%
ROIC
Revenue growth
125.1%

Insider activity, last 90 days

Net open-market
$-0.00m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Additional complications include increased risk of HIV infection, as 30% of HIV infections acquired through sexual transmission are attributable to HSV-2 infection. Given the predicted 6250 accumulation driven by the long half-life and the observed elevations of TBAs for the single-dose cohorts, doses at and below 1 mg daily were selected for the multiple-dose cohorts to characterize the lower end of the dose-response curve. …ASSEMBLY BIOSCIENCES, INC., 10-Q, period ended 2026-06-30, filed 2026-08-13

Read the full passage →